Literature DB >> 11572601

CpG stimulation of primary mouse B cells is blocked by inhibitory oligodeoxyribonucleotides at a site proximal to NF-kappaB activation.

P Lenert1, L Stunz, A K YI, A M Krieg, R F Ashman.   

Abstract

Bacterial DNA and CpG-oligodeoxyribonucleotides (ODN) are powerful B cell activators, inducing apoptosis protection, cell cycle entry, proliferation, costimulatory molecule expression, immunoglobulin (Ig) and interleukin-6 (IL-6) secretion. However, proximal events in B cell activation by ODN are only partially characterized, including the translocation of NF-kappaB to the nucleus. In this paper, we provide evidence that CpG-ODN-induced cell cycle entry and apoptosis protection are blocked by SN50 or gliotoxin and thus require NF-kappaB activation. NF-kappaB activation occurred within 30 minutes of stimulation of murine B cells with a phosphorothioate (S) CpG-ODN and persisted for up to 40 hours, with p50, p65, and c-Rel as the major components. Similar to other NF-kappaB inducers, CpG-ODN caused an early IkappaBalpha and IkappaBbeta degradation plus cleavage of the p50 precursor and subsequent NF-kappaB nuclear translocation. A group of closely related S-ODN, which specifically blocked CpG-induced B cell activation at submicromolar concentrations, also prevented NF-kappaB DNA binding and transcriptional activation. These inhibitory S-ODN differed from stimulatory S-ODN by having 2-3 G substitutions in the central motif. As inhibitory S-ODN did not directly interfere with the NF-kappaB DNA binding but prevented CpG-induced NF-kappaB nuclear translocation of p50, p65, and c-Rel and blocked p105, IkappaBalpha, and IkappaBbeta degradation, we concluded that their putative target must lie upstream of inhibitory kinase (IKK) activation.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11572601     DOI: 10.1089/108729001317022241

Source DB:  PubMed          Journal:  Antisense Nucleic Acid Drug Dev        ISSN: 1087-2906


  32 in total

Review 1.  Nucleic acid sensing receptors in systemic lupus erythematosus: development of novel DNA- and/or RNA-like analogues for treating lupus.

Authors:  P Lenert
Journal:  Clin Exp Immunol       Date:  2010-05-07       Impact factor: 4.330

2.  Sequences derived from self-RNA containing certain natural modifications act as suppressors of RNA-mediated inflammatory immune responses.

Authors:  Sibylle Tluk; Marion Jurk; Alexandra Forsbach; Risini Weeratna; Ulrike Samulowitz; Arthur M Krieg; Stefan Bauer; Jörg Vollmer
Journal:  Int Immunol       Date:  2009-03-30       Impact factor: 4.823

3.  Innate immune responses in lupus-prone Palmerston North mice: differential responses to LPS and bacterial DNA/CpG oligonucleotides.

Authors:  Petar Lenert; Adam Goeken; Barry S Handwerger; Robert F Ashman
Journal:  J Clin Immunol       Date:  2003-05       Impact factor: 8.317

Review 4.  Synthetic oligonucleotides as modulators of inflammation.

Authors:  Dennis Klinman; Hidekazu Shirota; Debra Tross; Takashi Sato; Sven Klaschik
Journal:  J Leukoc Biol       Date:  2008-04-22       Impact factor: 4.962

5.  Therapeutic implications of orally delivered immunomodulatory oligonucleotides.

Authors:  Dennis M Klinman
Journal:  Mol Ther       Date:  2015-02       Impact factor: 11.454

6.  Toll-like receptor (TLR) 3 immune modulation by unformulated small interfering RNA or DNA and the role of CD14 (in TLR-mediated effects).

Authors:  Cordula Weber; Christian Müller; Anja Podszuweit; Carmen Montino; Jörg Vollmer; Alexandra Forsbach
Journal:  Immunology       Date:  2012-05       Impact factor: 7.397

7.  TLR-9 activation of marginal zone B cells in lupus mice regulates immunity through increased IL-10 production.

Authors:  Petar Lenert; Rachel Brummel; Elizabeth H Field; Robert F Ashman
Journal:  J Clin Immunol       Date:  2005-01       Impact factor: 8.317

8.  Endosomal Toll-Like Receptors Mediate Enhancement of Interleukin-17A Production Triggered by Epstein-Barr Virus DNA in Mice.

Authors:  Marwa Shehab; Nour Sherri; Hadi Hussein; Noor Salloum; Elias A Rahal
Journal:  J Virol       Date:  2019-09-30       Impact factor: 5.103

Review 9.  Classification, mechanisms of action, and therapeutic applications of inhibitory oligonucleotides for Toll-like receptors (TLR) 7 and 9.

Authors:  Petar S Lenert
Journal:  Mediators Inflamm       Date:  2010-05-18       Impact factor: 4.711

10.  DNA-like class R inhibitory oligonucleotides (INH-ODNs) preferentially block autoantigen-induced B-cell and dendritic cell activation in vitro and autoantibody production in lupus-prone MRL-Fas(lpr/lpr) mice in vivo.

Authors:  Petar Lenert; Kei Yasuda; Liliana Busconi; Patrice Nelson; Courtney Fleenor; Radhika S Ratnabalasuriar; Peter L Nagy; Robert F Ashman; Ian R Rifkin; Ann Marshak-Rothstein
Journal:  Arthritis Res Ther       Date:  2009-05-28       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.